Interventional Devascularization Plus HVPG-Guided Carvedilol Therapy vs TIPS
Launched by AIR FORCE MILITARY MEDICAL UNIVERSITY, CHINA · Dec 11, 2019
Trial Information
Current as of June 05, 2025
Unknown status
Keywords
ClinConnect Summary
Gastric varices (GV) are present in around 20% of patients with cirrhosis. Bleeding from GV accounts for 10-20% of all variceal bleeding. GV are classified according to their location in the stomach and their relationship with esophageal varices (EV). Accordingly, GV are divided into gastroesophageal varices (GOV) and isolated gastric varices (IGV) . The management of type 1 GOV, which extend from the esophagus along the lesser curvature of the stomach, is similar to the management of EV. Historically, bleeding from type 2 GOV (i.e. GOV extending into the fundus), type 1 IGV (i.e. located i...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Liver cirrhosis diagnosed by clinical examination, imaging or biopsy
- • Patients with a previous history of variceal hemorrhage
- • Gastric variceal confirmed by an endoscopic examination, including IGV1 or IGV2
- • Aged 18 to 75 years
- • Adequate liver and kidney function, including Child-Turcotte-Pugh score \< 12, MELD score \<19, and serum creatinine less than 2 times the upper limit of normal.
- Exclusion Criteria:
- • Active variceal bleeding
- • Esophageal variceal, including GOV1 or GOV2 type, mainly esophageal varices;
- • Refractory ascites
- • Patients with contraindication to treatment of TIPS, including congestive heart failure, NYHA III and IV, pulmonary arterial hypertension(\>50mmHg), polycystic liver, intrahepatic duct dilatation, spontaneous bacterial peritonitis, hepatic encephalopathy
- • Patients with contraindication to treatment of Carvedilol, including asthma, insulin-dependent diabetes, peripheral vascular diseases
- • Child-Turcotte-Pugh score \>=12, or MELD score \>=19
- • Budd-Chiari syndrome
- • The main portal vein thrombosis is greater than 50%
- • Malignancies
- • An uncontrolled infection
- • Previously treated with TIPS, splenectomy pericardia vascular disconnection, or surgical shunts
- • HIV or HIV related illness
- • Allergic to contrast agent
- • Lactating or pregnant
- • Non-compliant patients
About Air Force Military Medical University, China
The Air Force Military Medical University (AFMMU) in China is a prestigious institution dedicated to advancing military medicine and healthcare research. With a strong emphasis on clinical trials and innovative medical practices, AFMMU integrates cutting-edge scientific research with practical applications to enhance the health and well-being of military personnel and the broader community. The university fosters collaboration among various disciplines, promoting a robust environment for training healthcare professionals and conducting impactful studies that address critical health challenges. Through its commitment to excellence and rigorous scientific methodology, AFMMU plays a pivotal role in shaping the future of military and civilian healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Jun Tie, M.D.,Ph.D.
Principal Investigator
Air Force Military Medical University, China
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials